|
Title
|
Status
|
|
|
Recruiting
in 1 of 1 locations
|
|
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in patients with hematologic cancer.
|
|
|
Recruiting
in 1 of 1 locations
|
|
This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies. The study will also characterize Cliquinol's safety, tolerability and pharmacodynamic effect.
|
|
|
Pending
in 1 of 1 locations
|
|
The purpose of this study is to determine if maintenance therapy with ofatumumab will prolong remission in patients with CLL who have responded to second or third line treatment. This study will also evaluate the safety of ofatumumab maintenance compared to observation (the current standard of care). This study was co-developed with the HOVON and NORDIC CLL group and will be conducted as a collaborative effort with GSK.
|
|
|
Recruiting
in 3 of 3 locations
|
|
The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
|
|
|
Recruiting
in 1 of 1 locations
|
|
The purpose of this study is to determine whether the administration of donor lymphocytes depleted of alloreactive T-cells (ATIR™) after a T-cell depleted stem cell transplant from a related, haploidentical donor enhances survival by improving the immune effect against infections while preventing graft-versus-host disease .
|
|
|
Recruiting
in 4 of 4 locations
|
|
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with
chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively
uncommon and therefore not well studied. Treatment approaches are patterned after the more
common B-cell lymphomas. T-cell lymphomas are more likely to relapse following standard
therapy than are B-cell lymphomas. New therapies are needed for T-cell lymphomas. In this
study, we will administer the drug called lenalidomide as a pill to patients with T-cell
lymphoma. The goals are to determine if the drug can induce regression of the cancer, and to
determine if the treatment is well tolerated in this patient group. This study will take
place at six cancer centres across Canada.
|
|
|
Recruiting
in 0 of 3 locations
|
|
RATIONALE: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) and pilocarpine may help to relieve chronic xerostomia (dry mouth). It is not yet known which remedy is more effective in treating chronic dry mouth caused by radiation therapy in patients with head and neck cancer. PURPOSE: This randomized phase II/III trial is studying ALTENS to see how well it works compared with pilocarpine in treating chronic dry mouth caused by radiation therapy in patients with head and neck cancer.
|
|
|
Recruiting
in 4 of 8 locations
|
|
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near
a tumor to kill tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided
implant radiation therapy works in treating patients with locally recurrent prostate cancer
previously treated with external-beam radiation therapy.
|
|
|
Recruiting
in 4 of 4 locations
|
|
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with advanced, indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).
|
|
|
Recruiting
in 1 of 1 locations
|
|
The substudy is a multicenter, open-label study consisting of a subset of the patients in Cephalon study C18083/3064/NL/MN who are receiving the investigational treatment (BR), for the purpose of assessing the effect of bendamustine on cardiac repolarization in adults with advanced indolent NHL or MCL.
|
